{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:06:42Z","timestamp":1792782402273,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T00:00:00Z","timestamp":1738108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T00:00:00Z","timestamp":1738108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003042","name":"Else Kr\u00f6ner-Fresenius-Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010215","name":"Deutsche Diabetes Gesellschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010215","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010447","name":"Deutsches Zentrum f\u00fcr Herz-Kreislaufforschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010447","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Medizinische Fakult\u00e4t Heidelberg der Universit\u00e4t Heidelberg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Neuroradiol"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cardiovascular risk management is beneficial, but stringent glycemic control does not prevent the progression of distal sensorimotor polyneuropathy (DSPN). Persistent hyperglycemia-induced alterations and cardiovascular factors may contribute to diabetes-associated nerve damage. This study aimed to evaluate the correlation between skin auto-fluorescence (sAF), an indicator of dermal advanced glycation end-product (AGE) accumulations, cardiovascular risk, and changes in peripheral nerve integrity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Sixty-two individuals with type\u00a02 diabetes (T2D) (20\u00a0women and 42\u00a0men), including 29 diagnosed with DSPN (7\u00a0women and 22\u00a0men), and 10\u00a0healthy controls (HC) underwent diffusion tensor MR imaging of the sciatic nerve to assess fractional anisotropy (FA), an indicator of nerve structural integrity. sAF measurements were combined with clinical, serological, and electrophysiological evaluations. Arterial stiffness was assessed via pulse wave velocity (PWV).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      sAF (HC 2.1\u202f\u00b1\u20090.25 AU, nDSPN 2.3\u202f\u00b1\u20090.47, DSPN 2.6\u202f\u00b1\u20090.43;\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u20090.005) was higher in individuals with DSPN compared to HC (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u20090.010) and individuals without DSPN (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u20090.035). Within the group of T2D FA correlated negatively with sAF (r\u202f=\u2009\u22120.49,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&lt;\u20090.001), PWV (r\u202f=\u2009\u22120.40,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u20090.009) and high-sensitivity troponin\u00a0T (hsTNT), a\u00a0marker of microvascular damage (r\u202f=\u2009\u22120.39,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&lt;\u20090.001). In DSPN, sAF correlated positively with hsTNT (r\u202f=\u20090.58,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u20090.005) and with PWV (r\u202f=\u20090.52,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u20090.007), the sciatic nerve\u2019s FA correlated negatively with PWV (r\u202f=\u2009\u22120.47,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u20090.010).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study is the first to show close correlations between reduced peripheral nerve integrity and both intradermal AGE deposition and arterial stiffness in individuals with T2D. These findings highlight a\u00a0mechanistic link between glycation-related vascular injury and neuronal damage emphasizing the importance of cardiovascular risk management in preventing DSPN.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00062-024-01493-1","type":"journal-article","created":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T16:44:27Z","timestamp":1738169067000},"page":"385-394","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Intradermal Advanced Glycation End-products Relate to Reduced Sciatic Nerve Structural Integrity in Type\u00a02 Diabetes"],"prefix":"10.1007","volume":"35","author":[{"given":"Christoph M.","family":"Mooshage","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Tsilingiris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Schimpfle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Fleming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Herzig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Szendroedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Heiland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Bendszus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Kopf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Kurz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"Jende","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0745-1587","authenticated-orcid":false,"given":"Zoltan","family":"Kender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,29]]},"reference":[{"key":"1493_CR1","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41572-019-0092-1","volume":"5","author":"EL Feldman","year":"2019","unstructured":"Feldman EL, Callaghan BC, Pop-Busui R, Zochodne DW, Wright DE, Bennett DL, Bril V, Russell JW, Viswanathan V. Diabetic neuropathy. Nat Rev Dis Primers. 2019;5:41.","journal-title":"Nat Rev Dis Primers"},{"key":"1493_CR2","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12902-021-00697-7","volume":"21","author":"S Papachristou","year":"2021","unstructured":"Papachristou S, Pafili K, Papanas N. Skin AGEs and diabetic neuropathy. BMC Endocr Disord. 2021;21:28.","journal-title":"BMC Endocr Disord"},{"key":"1493_CR3","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1177\/193229680800200407","volume":"2","author":"EG Gerrits","year":"2008","unstructured":"Gerrits EG, Lutgers HL, Kleefstra N, Groenier KH, Smit AJ, Gans RO, Bilo HJ. Skin advanced glycation end product accumulation is poorly reflected by glycemic control in type\u00a02 diabetic patients (ZODIAC-9). J\u00a0Diabetes Sci Technol. 2008;2:572\u20137.","journal-title":"J Diabetes Sci Technol"},{"key":"1493_CR4","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1007\/s00125-004-1451-2","volume":"47","author":"R Meerwaldt","year":"2004","unstructured":"Meerwaldt R, Graaff R, Oomen PHN, Links TP, Jager JJ, Alderson NL, Thorpe SR, Baynes JW, Gans ROB, Smit AJ. Simple non-invasive assessment of advanced glycation endproduct accumulation. Diabetologia. 2004;47:1324\u201330.","journal-title":"Diabetologia"},{"key":"1493_CR5","doi-asserted-by":"publisher","first-page":"e009833","DOI":"10.1161\/JAHA.118.009833","volume":"7","author":"I Cavero-Redondo","year":"2018","unstructured":"Cavero-Redondo I, Soriano-Cano A, Alvarez-Bueno C, Cunha PG, Martinez-Hortelano JA, Garrido-Miguel M, Berlanga-Macias C, Martinez-Vizcaino V. Skin Autofluorescence-Indicated Advanced Glycation End Products as Predictors of Cardiovascular and All-Cause Mortality in High-Risk Subjects: A\u00a0Systematic Review and Meta-analysis. J\u00a0Am Heart Assoc. 2018;7:e9833.","journal-title":"J Am Heart Assoc"},{"key":"1493_CR6","doi-asserted-by":"publisher","first-page":"33","DOI":"10.4161\/derm.17999","volume":"4","author":"C den Engelsen","year":"2012","unstructured":"den Engelsen C, van den Donk M, Gorter KJ, Salome PL, Rutten GE. Advanced glycation end products measured by skin autofluorescence in a\u00a0population with central obesity. Dermatoendocrinol. 2012;4:33\u20138.","journal-title":"Dermatoendocrinol"},{"key":"1493_CR7","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.numecd.2013.04.004","volume":"23","author":"NC Chilelli","year":"2013","unstructured":"Chilelli NC, Burlina S, Lapolla A. AGEs, rather than hyperglycemia, are responsible for microvascular complications in diabetes: a\u00a0\u201cglycoxidation-centric\u201d point of view. Nutr Metab Cardiovasc Dis. 2013;23:913\u20139.","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"1493_CR8","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.molmet.2013.11.006","volume":"3","author":"A Stirban","year":"2014","unstructured":"Stirban A, Gawlowski T, Roden M. Vascular effects of advanced glycation endproducts: Clinical effects and molecular mechanisms. Mol Metab. 2014;3:94\u2013108.","journal-title":"Mol Metab"},{"key":"1493_CR9","doi-asserted-by":"publisher","first-page":"188","DOI":"10.4093\/dmj.2017.0105","volume":"42","author":"SY Rhee","year":"2018","unstructured":"Rhee SY, Kim YS. The Role of Advanced Glycation End Products in Diabetic Vascular Complications. Diabetes Metab\u00a0J. 2018;42:188\u201395.","journal-title":"Diabetes Metab J"},{"key":"1493_CR10","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1007\/s13300-022-01285-1","volume":"13","author":"AM Diallo","year":"2022","unstructured":"Diallo AM, Jaisson S, Barriquand R, Lukas C, Barraud S, Decoudier B, Francois M, Ly S, Mahmoudi R, Arndt C, Nazeyrollas P, Gillery P, Delemer B. Association Between the Tissue and Circulating Advanced Glycation End-Products and the Micro- and Macrovascular Complications in Type\u00a01 Diabetes: The DIABAGE Study. Diabetes Ther. 2022;13:1531\u201346.","journal-title":"Diabetes Ther"},{"key":"1493_CR11","doi-asserted-by":"publisher","first-page":"13264","DOI":"10.1038\/s41598-021-92630-0","volume":"11","author":"D Indyk","year":"2021","unstructured":"Indyk D, Bronowicka-Szydelko A, Gamian A, Kuzan A. Advanced glycation end products and their receptors in serum of patients with type\u00a02 diabetes. Sci Rep. 2021;11:13264.","journal-title":"Sci Rep"},{"key":"1493_CR12","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1002\/ana.25182","volume":"83","author":"JME Jende","year":"2018","unstructured":"Jende JME, Groener JB, Oikonomou D, Heiland S, Kopf S, Pham M, Nawroth P, Bendszus M, Kurz FT. Diabetic neuropathy differs between type\u00a01 and type\u00a02 diabetes: Insights from magnetic resonance neurography. Ann Neurol. 2018;83:588\u201398.","journal-title":"Ann Neurol"},{"key":"1493_CR13","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa032782","volume":"352","author":"S Tesfaye","year":"2005","unstructured":"Tesfaye S, Chaturvedi N, Eaton SE, Ward JD, Manes C, Ionescu-Tirgoviste C, Witte DR, Fuller JH, Group EPCS. Vascular risk factors and diabetic neuropathy. N\u00a0Engl J Med. 2005;352:341\u201350.","journal-title":"N Engl J Med"},{"key":"1493_CR14","doi-asserted-by":"publisher","first-page":"e13380","DOI":"10.1111\/eci.13380","volume":"51","author":"AS Antonopoulos","year":"2021","unstructured":"Antonopoulos AS, Siasos G, Oikonomou E, Gouliopoulos N, Konsola T, Tsigkou V, Moschos M, Tentolouris N, Kassi E, Paschou SA, Thanopoulou A, Vavuranakis M, Stone P, Antoniades C, Tousoulis D. Arterial stiffness and microvascular disease in type\u00a02 diabetes. Eur J Clin Invest. 2021;51:e13380.","journal-title":"Eur J Clin Invest"},{"key":"1493_CR15","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.atherosclerosis.2008.12.027","volume":"205","author":"CR Cardoso","year":"2009","unstructured":"Cardoso CR, Ferreira MT, Leite NC, Barros PN, Conte PH, Salles GF. Microvascular degenerative complications are associated with increased aortic stiffness in type\u00a02 diabetic patients. Atherosclerosis. 2009;205:472\u20136.","journal-title":"Atherosclerosis"},{"key":"1493_CR16","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1002\/jmri.25415","volume":"45","author":"M Vaeggemose","year":"2017","unstructured":"Vaeggemose M, Pham M, Ringgaard S, Tankisi H, Ejskjaer N, Heiland S, Poulsen PL, Andersen H. Diffusion tensor imaging MR neurography for the detection of polyneuropathy in type\u00a01 diabetes. J\u00a0Magn Reson Imaging. 2017;45:1125\u201334.","journal-title":"J Magn Reson Imaging"},{"key":"1493_CR17","series-title":"Type","volume-title":"Association of Small Fiber Function with Microvascular Perfusion of Peripheral Nerves in Patients with","author":"CM Mooshage","year":"2023","unstructured":"Mooshage CM, Schimpfle L, Kender Z, Tsilingiris D, Aziz-Safaie T, Hohmann A, Szendroedi J, Nawroth P, Sturm V, Heiland S, Bendszus M, Kopf S, Kurz FT, Jende JME. Association of Small Fiber Function with Microvascular Perfusion of Peripheral Nerves in Patients with. Type, Vol. 2. Diabetes : Study using Quantitative Sensory Testing and Magnetic Resonance Neurography. Clin Neuroradiol.  2023."},{"key":"1493_CR18","doi-asserted-by":"publisher","first-page":"713","DOI":"10.2337\/db19-1094","volume":"69","author":"JME Jende","year":"2020","unstructured":"Jende JME, Groener JB, Kender Z, Hahn A, Morgenstern J, Heiland S, Nawroth PP, Bendszus M, Kopf S, Kurz FT. Troponin\u00a0T Parallels Structural Nerve Damage in Type\u00a02 Diabetes: A\u00a0Cross-sectional Study Using Magnetic Resonance Neurography. Diabetes. 2020;69:713\u201323.","journal-title":"Diabetes"},{"key":"1493_CR19","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1002\/acn3.51563","volume":"9","author":"JME Jende","year":"2022","unstructured":"Jende JME, Mooshage C, Kender Z, Schimpfle L, Juerchott A, Heiland S, Nawroth P, Bendszus M, Kopf S, Kurz FT. Sciatic nerve microvascular permeability in type\u00a02 diabetes decreased in patients with neuropathy. Ann Clin Transl Neurol. 2022;9:830\u201340.","journal-title":"Ann Clin Transl Neurol"},{"key":"1493_CR20","doi-asserted-by":"publisher","first-page":"811085","DOI":"10.3389\/fnins.2021.811085","volume":"15","author":"JME Jende","year":"2021","unstructured":"Jende JME, Mooshage C, Kender Z, Kopf S, Groener JB, Heiland S, Juerchott A, Nawroth P, Bendszus M, Kurz FT. Magnetic Resonance Neurography Reveals Smoking-Associated Decrease in Sciatic Nerve Structural Integrity in Type\u00a02 Diabetes. Front Neurosci. 2021;15:811085.","journal-title":"Front Neurosci"},{"key":"1493_CR21","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1007\/s00125-005-1828-x","volume":"48","author":"R Meerwaldt","year":"2005","unstructured":"Meerwaldt R, Links TP, Graaff R, Hoogenberg K, Lefrandt JD, Baynes JW, Gans RO, Smit AJ. Increased accumulation of skin advanced glycation end-products precedes and correlates with clinical manifestation of diabetic neuropathy. Diabetologia. 2005;48:1637\u201344.","journal-title":"Diabetologia"},{"key":"1493_CR22","volume-title":"Statistical power analysis for the behavioral sciences. Hillsdale, N.J., L","author":"J Cohen","year":"1988","unstructured":"Cohen J. Statistical power analysis for the behavioral sciences. Hillsdale, N.J., L. Erlbaum; 1988."},{"key":"1493_CR23","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1055\/s-0034-1366435","volume":"122","author":"D Ziegler","year":"2014","unstructured":"Ziegler D, Keller J, Maier C, Pannek J, Diabetes GA. Diabetic neuropathy. Exp Clin Endocrinol. 2014;122:406\u201315.","journal-title":"Exp Clin Endocrinol"},{"key":"1493_CR24","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.2337\/dc10-1303","volume":"33","author":"S Tesfaye","year":"2010","unstructured":"Tesfaye S, Boulton AJ, Dyck PJ, Freeman R, Horowitz M, Kempler P, Lauria G, Malik RA, Spallone V, Vinik A, Bernardi L, Valensi P, Toronto Diabetic Neuropathy Expert G. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010;33:2285\u201393.","journal-title":"Diabetes Care"},{"key":"1493_CR25","doi-asserted-by":"crossref","unstructured":"Mooshage CM, Tsilingiris, D., Schimpfle, L., Seebauer, L., Eledsouky, O., Aziz-Safaie, T., Hohmann, A., Herzig, S., Szendroedi, J., Nawroth, P., Heiland, S., Bendszus, M., Kurz, F., Kopf, S., Jende, J., Kender Z.,: A\u00a0diminished sciatic nerve structural integrity is associated with distinct peripheral sensory phenotypes in individuals with type\u00a02 diabetes. Diabetologia 2024;67(2):275\u201389.","DOI":"10.1007\/s00125-023-06050-y"},{"key":"1493_CR26","doi-asserted-by":"publisher","first-page":"517","DOI":"10.2337\/dc07-1755","volume":"31","author":"EG Gerrits","year":"2008","unstructured":"Gerrits EG, Lutgers HL, Kleefstra N, Graaff R, Groenier KH, Smit AJ, Gans RO, Bilo HJ. Skin autofluorescence: a\u00a0tool to identify type\u00a02 diabetic patients at risk for developing microvascular complications. Diabetes Care. 2008;31:517\u201321.","journal-title":"Diabetes Care"},{"key":"1493_CR27","doi-asserted-by":"publisher","first-page":"891442","DOI":"10.3389\/fendo.2022.891442","volume":"13","author":"E Al-Saoudi","year":"2022","unstructured":"Al-Saoudi E, Christensen MMB, Nawroth P, Fleming T, Hommel EE, Jorgensen ME, Fleischer J, Hansen CS. Advanced glycation end-products are associated with diabetic neuropathy in young adults with type\u00a01 diabetes. Front Endocrinol (lausanne). 2022;13:891442.","journal-title":"Front Endocrinol (lausanne)"},{"key":"1493_CR28","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1097\/WCO.0b013e328357a797","volume":"25","author":"BC Callaghan","year":"2012","unstructured":"Callaghan BC, Hur J, Feldman EL. Diabetic neuropathy: one disease or two? Curr Opin Neurol. 2012;25:536\u201341.","journal-title":"Curr Opin Neurol"},{"key":"1493_CR29","first-page":"CD007543","volume":"6","author":"BC Callaghan","year":"2012","unstructured":"Callaghan BC, Little AA, Feldman EL, Hughes RA. Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database Syst Rev. 2012;6:CD7543.","journal-title":"Cochrane Database Syst Rev"},{"key":"1493_CR30","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.jdiacomp.2018.06.014","volume":"32","author":"AO Stirban","year":"2018","unstructured":"Stirban AO, Bondor CI, Florea B, Veresiu IA, Gavan NA. Skin autofluorescence: Correlation with measures of diabetic sensorimotor neuropathy. J\u00a0Diabetes Complications. 2018;32:851\u20136.","journal-title":"J Diabetes Complications"},{"key":"1493_CR31","doi-asserted-by":"publisher","first-page":"953","DOI":"10.2174\/138161208784139774","volume":"14","author":"K Sugimoto","year":"2008","unstructured":"Sugimoto K, Yasujima M, Yagihashi S. Role of advanced glycation end products in diabetic neuropathy. Curr Pharm Des. 2008;14:953\u201361.","journal-title":"Curr Pharm Des"},{"key":"1493_CR32","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1093\/nar\/gkad085","volume":"51","author":"Z Han","year":"2023","unstructured":"Han Z, Andrs M, Madhavan BK, Kaymak S, Sulaj A, Kender Z, Kopf S, Kihm L, Pepperkok R, Janscak P, Nawroth P, Kumar V. The importance of nuclear RAGE-Mcm2 axis in diabetes or cancer-associated replication stress. Nucleic Acids Res. 2023;51:2298\u2013318.","journal-title":"Nucleic Acids Res"},{"key":"1493_CR33","doi-asserted-by":"publisher","first-page":"e83084","DOI":"10.1371\/journal.pone.0083084","volume":"8","author":"MA den Dekker","year":"2013","unstructured":"den Dekker MA, Zwiers M, van den Heuvel ER, de Vos LC, Smit AJ, Zeebregts CJ, Oudkerk M, Vliegenthart R, Lefrandt JD, Mulder DJ. Skin autofluorescence, a\u00a0non-invasive marker for AGE accumulation, is associated with the degree of atherosclerosis. Plos One. 2013;8:e83084.","journal-title":"Plos One"},{"key":"1493_CR34","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1161\/ATVBAHA.112.300016","volume":"33","author":"LC de Vos","year":"2013","unstructured":"de Vos LC, Noordzij MJ, Mulder DJ, Smit AJ, Lutgers HL, Dullaart RP, Kamphuisen PW, Zeebregts CJ, Lefrandt JD. Skin autofluorescence as a\u00a0measure of advanced glycation end products deposition is elevated in peripheral artery disease. Arterioscler Thromb Vasc Biol. 2013;33:131\u20138.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1493_CR35","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s12933-021-01296-5","volume":"20","author":"A Birukov","year":"2021","unstructured":"Birukov A, Cuadrat R, Polemiti E, Eichelmann F, Schulze MB. Advanced glycation end-products, measured as skin autofluorescence, associate with vascular stiffness in diabetic, pre-diabetic and normoglycemic individuals: a\u00a0cross-sectional study. Cardiovasc Diabetol. 2021;20:110.","journal-title":"Cardiovasc Diabetol"},{"key":"1493_CR36","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1177\/1479164118785314","volume":"15","author":"K Yoshioka","year":"2018","unstructured":"Yoshioka K. Skin autofluorescence is associated with high-sensitive cardiac troponin T, a\u00a0circulating cardiac biomarker, in Japanese patients with diabetes: A\u00a0cross-sectional study. Diab Vasc Dis Res. 2018;15:559\u201366.","journal-title":"Diab Vasc Dis Res"},{"key":"1493_CR37","first-page":"177","volume":"8","author":"RE Schmieder","year":"2012","unstructured":"Schmieder RE, Goebel M, Bramlage P. Barriers to cardiovascular risk prevention and management in Germany\u2014an analysis of the EURIKA study. Vasc Health Risk Manag. 2012;8:177\u201386.","journal-title":"Vasc Health Risk Manag"},{"key":"1493_CR38","doi-asserted-by":"publisher","first-page":"290","DOI":"10.2337\/db22-0548","volume":"72","author":"CM Mooshage","year":"2023","unstructured":"Mooshage CM, Schimpfle L, Kender Z, Szendroedi J, Heiland S, Nawroth P, Bendszus M, Kopf S, Kurz FT, Jende JME. Diametrical Effects of Glucose Levels on Microvascular Permeability of Peripheral Nerves in Patients With Type\u00a02 Diabetes With and Without Diabetic Neuropathy. Diabetes. 2023;72:290\u20138.","journal-title":"Diabetes"},{"key":"1493_CR39","first-page":"CD004572","volume":"2007","author":"C Chalk","year":"2007","unstructured":"Chalk C, Benstead TJ, Moore F. Aldose reductase inhibitors for the treatment of diabetic polyneuropathy. Cochrane Database Syst Rev. 2007;2007:CD4572.","journal-title":"Cochrane Database Syst Rev"},{"key":"1493_CR40","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.2337\/dc05-2370","volume":"29","author":"N Hotta","year":"2006","unstructured":"Hotta N, Akanuma Y, Kawamori R, Matsuoka K, Oka Y, Shichiri M, Toyota T, Nakashima M, Yoshimura I, Sakamoto N, Shigeta Y. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial. Diabetes Care. 2006;29:1538\u201344.","journal-title":"Diabetes Care"}],"container-title":["Clinical Neuroradiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00062-024-01493-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00062-024-01493-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00062-024-01493-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T15:02:29Z","timestamp":1750172549000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00062-024-01493-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,29]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["1493"],"URL":"https:\/\/doi.org\/10.1007\/s00062-024-01493-1","relation":{},"ISSN":["1869-1439","1869-1447"],"issn-type":[{"value":"1869-1439","type":"print"},{"value":"1869-1447","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,29]]},"assertion":[{"value":"24 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.M.\u00a0Mooshage, D.\u00a0Tsilingiris, L.\u00a0Schimpfle, T.\u00a0Fleming, S.\u00a0Herzig, J.\u00a0Szendroedi, S.\u00a0Heiland, M.\u00a0Bendszus, S.\u00a0Kopf, F.\u00a0Kurz, J.\u00a0Jende and Z.\u00a0Kender declarethat they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}